Compass Therapeutics (NASDAQ:CMPX) Hits New 52-Week High at $5.40
Compass Therapeutics (NASDAQ:CMPX) Hits New 52-Week High at $5.40
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) reached a new 52-week high on Thursday . The stock traded as high as $5.40 and last traded at $5.14, with a volume of 20745 shares. The stock had previously closed at $4.79.
指南針治療公司(納斯達克：cmpx-get評級)週四創下52周新高。該股盤中一度漲至5.4美元，最新報5.14美元，成交量為20745股。該股此前收盤價為4.79美元。
Analyst Ratings Changes
分析師評級發生變化
Several equities research analysts have weighed in on CMPX shares. Raymond James upped their target price on Compass Therapeutics from $5.00 to $8.00 and gave the stock an "outperform" rating in a research note on Thursday, November 10th. EF Hutton Acquisition Co. I started coverage on Compass Therapeutics in a research note on Friday, December 16th. They set a "buy" rating and a $10.30 target price for the company. HC Wainwright cut their target price on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Thursday, November 3rd. Finally, LADENBURG THALM/SH SH upped their target price on Compass Therapeutics to $9.00 in a research note on Wednesday, November 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $9.46.
幾位股票研究分析師加入了對CMPX股票的追捧。雷蒙德·詹姆斯在11月10日(星期四)的一份研究報告中將Compass Treateutics的目標價從5.00美元上調至8.00美元，並給予該股“跑贏大盤”的評級。EF Hutton Acquisition Co.I在12月16日星期五的一份研究報告中開始報道Compass治療公司。他們為該公司設定了“買入”評級和10.30美元的目標價。11月3日星期四，HC Wainwright在一份研究報告中將Compass Treateutics的目標價從12.00美元下調至10.00美元，併為該公司設定了“買入”評級。最後，拉登堡THALM/SH SH在11月16日星期三的一份研究報告中將他們對Compass治療公司的目標價格上調至9.00美元。根據MarketBeat.com的數據，五位股票研究分析師對該股的評級為買入，該公司的平均評級為“買入”，共識目標價為9.46美元。
Compass Therapeutics Stock Performance
Compass Treateutics股票表現
The firm's fifty day moving average price is $4.00 and its 200-day moving average price is $3.18.
該公司的50日移動均線價格為4.00美元，200日移動均線價格為3.18美元。
Insider Transactions at Compass Therapeutics
羅盤治療公司的內幕交易
In related news, CEO Thomas J. Schuetz acquired 15,000 shares of the firm's stock in a transaction that occurred on Monday, September 26th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $34,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,421,873 shares of the company's stock, valued at approximately $12,307,651.71. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Thomas J. Schuetz acquired 15,000 shares of the firm's stock in a transaction that occurred on Monday, September 26th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $34,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,421,873 shares of the company's stock, valued at approximately $12,307,651.71. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Orbimed Advisors Llc acquired 402,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 8th. The stock was bought at an average price of $3.21 per share, with a total value of $1,290,420.00. Following the completion of the acquisition, the director now directly owns 15,219,994 shares of the company's stock, valued at $48,856,180.74. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 427,000 shares of company stock worth $1,347,670. Corporate insiders own 29.80% of the company's stock.
在相關新聞中，首席執行官託馬斯·J·舒茨在9月26日星期一的一次交易中收購了該公司15,000股股票。收購股票的平均成本為每股2.27美元，交易總額為34,050.00美元。收購完成後，首席執行官現在直接擁有5,421,873股公司股票，價值約12,307,651.71美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可在這個環節。在相關新聞中，首席執行官託馬斯·J·舒茨在9月26日星期一的一次交易中收購了該公司15,000股股票。收購股票的平均成本為每股2.27美元，交易總額為34,050.00美元。收購完成後，首席執行官現在直接擁有5,421,873股公司股票，價值約12,307,651.71美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可在這個環節。此外，董事在11月8日星期二的一次交易中收購了402,000股該公司的股票。這隻股票是以每股3.21美元的平均價格購買的，總價值為1290,420.00美元。收購完成後，董事現在直接擁有15,219,994股公司股票，價值48,856,180.74美元。關於這次購買的披露可以找到這裏。在過去的90天裏，內部人士購買了427,000股公司股票，價值1,347,670美元。公司內部人士持有該公司29.80%的股份。
Institutional Trading of Compass Therapeutics
指南針治療公司的機構交易
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Compass Therapeutics by 58.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,380,623 shares of the company's stock worth $5,428,000 after acquiring an additional 878,650 shares during the period. Eventide Asset Management LLC bought a new position in shares of Compass Therapeutics during the 3rd quarter worth about $2,509,000. BlackRock Inc. boosted its position in shares of Compass Therapeutics by 433.9% during the 3rd quarter. BlackRock Inc. now owns 872,497 shares of the company's stock worth $1,989,000 after purchasing an additional 709,071 shares in the last quarter. Silverarc Capital Management LLC bought a new position in shares of Compass Therapeutics during the 3rd quarter worth about $598,000. Finally, Renaissance Technologies LLC boosted its position in shares of Compass Therapeutics by 397.5% during the 2nd quarter. Renaissance Technologies LLC now owns 66,165 shares of the company's stock worth $175,000 after purchasing an additional 52,865 shares in the last quarter. 54.27% of the stock is currently owned by institutional investors and hedge funds.
一些大型投資者最近買賣了該公司的股票。先鋒集團在第三季度增持了58.5%的Compass Treateutics股份。先鋒集團在此期間增持了878,650股，目前持有2,380,623股該公司股票，價值5,428,000美元。Evende Asset Management LLC在第三季度購買了Compass治療公司股票的新頭寸，價值約2,509,000美元。貝萊德股份有限公司在第三季度將其在羅盤治療公司的股票持倉增加了433.9%。貝萊德股份有限公司在上個季度增持了709,071股後，現在持有872,497股該公司股票，價值1,989,000美元。SilverarcCapital Management LLC在第三季度購買了Compass治療公司股票的新頭寸，價值約598,000美元。最後，復興科技有限責任公司在第二季度將其在Compass治療公司的股票持有量增加了397.5%。復興科技有限責任公司現在擁有66,165股該公司股票，價值17.5萬美元，上個季度又購買了52,865股。54.27%的股票目前由機構投資者和對衝基金持有。
About Compass Therapeutics
關於指南針治療公司
(Get Rating)
(獲取評級)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
Compass治療公司是一家專注於臨牀階段腫瘤學的生物製藥公司，致力於開發基於抗體的療法來治療各種人類疾病。該公司處於臨牀開發階段的候選產品包括CTX-009和CTX-471，CTX-009是一種研究中的雙特異性抗體，可以阻斷對血管生成和腫瘤血管形成至關重要的Delta-like配體4/Notch和血管內皮生長因子A信號通路；以及CTX-471，是CD137的激動劑，是一種IgG4單抗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- 免費獲取StockNews.com關於指南針治療的研究報告(CMPX)
- Lucid Motors面臨的現實可能會給看漲的看法蒙上陰影
- 機構將Rite Aid的股票跌至谷底
- 這就是為什麼你應該避開聯邦快遞的反彈
- 維京治療公司股票為何暴漲
- 耐克公司業績和前景走高
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《指南針治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Compass Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。